Alnylam Pharmaceuticals, Inc.
ALNYLast close · Oct 16, 2026231.83−2.20 (−0.94%)
Market cap$31.0B
Key indicators
Revenue3.7B+65.2% on a year earlier
74.9M
219.8M
492.9M
844.3M
1.0B
1.8B
2.2B
3.7B
5.5B
6.9B
8.3B
Fiscal year
FY201818
FY201919
FY202020
FY202121
FY202222
FY202323
FY202424
FY202525
FY2026E26E
FY2027E27E
FY2028E28E
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026E | FY2027E | FY2028E |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | |||||||||||
| 74.9M | 219.8M+193.4% | 492.9M+124.3% | 844.3M+71.3% | 1.0B+22.9% | 1.8B+76.2% | 2.2B+23.0% | 3.7B+65.2% | 5.5B | 6.9B | 8.3B | |
| — | 193.4% | 124.3% | 71.3% | 22.9% | 76.2% | 23.0% | 65.2% | 47.3% | 26.7% | 19.2% | |
| — | -$8.11 | -$7.46+8.0% | -$7.20+3.5% | -$9.30−29.2% | -$3.52+62.2% | -$2.18+38.1% | $2.33+206.9% | $6.66 | $10.02 | $12.34 | |
| Profitability | |||||||||||
| -1087.6% | -427.5%+660.1 pt | -168.1%+259.4 pt | -83.9%+84.2 pt | -75.7%+8.3 pt | -15.4%+60.2 pt | -7.9%+7.6 pt | 13.5%+21.4 pt | · | · | · | |
| -1016.6% | -403.2%+613.3 pt | -174.1%+229.1 pt | -101.0%+73.1 pt | -109.0%−8.0 pt | -24.1%+85.0 pt | -12.4%+11.7 pt | 8.4%+20.8 pt | · | · | · | |
| -58.5% | -61.6%−3.1 pt | -84.5%−22.9 pt | -145.0%−60.5 pt | 714.9%+859.9 pt | 199.5%−515.4 pt | -414.6%−614.1 pt | 39.8%+454.4 pt | · | · | · | |
| Cash | |||||||||||
| -689.5M | -418.6M+39.3% | -685.3M−63.7% | -718.1M−4.8% | -613.3M+14.6% | 41.9M+106.8% | -42.6M−201.5% | 465.4M+1192.7% | · | · | · | |
| -920.5% | -190.5%+730.0 pt | -139.1%+51.4 pt | -85.0%+54.0 pt | -59.1%+25.9 pt | 2.3%+61.4 pt | -1.9%−4.2 pt | 12.5%+14.4 pt | · | · | · | |
| Balance sheet | |||||||||||
| — | — | — | — | -6.43x | -4.63x+1.80x | 15.27x+19.90x | 1.28x−14.00x | · | · | · | |
| — | 109.26M | 114.99M+5.2% | 118.45M+3.0% | 121.69M+2.7% | 124.91M+2.6% | 127.65M+2.2% | 134.68M+5.5% | · | · | · | |
E = analyst consensus (revenue and EPS only). From the 10-K, as accepted by the SEC; the shaded column is the latest period.